ImmunityBio, Inc. — Director's Dealing 2022

Jun 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2022-06-14

Reporting Person: Cohen Cheryl (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-14	Stock Option (right to buy)	$2.98	A	167937	Acquired	2032-06-14	Common Stock (167937.0)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2023 or the date immediately preceding the 2023 annual meeting of stockholders.